InteRNA Technologies BV and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for prostate cancer.
Under the collaboration with Jack Schalken at the Laboratory of Experimental Urology, InteRNA’s lentiviral-based miRNA over-expression library will be applied to identify the biological role of individual miRNAs as potential novel therapeutic targets in prostate cancer.
“We are very excited about this collaboration with Professor Schalken, a renowned investigator in the prostate cancer field, as it allows for functional screens in diverse cell-based assays, in a lab with extensive knowledge of prostate cancer,” said Roel Schaapveld, Chief Operating Officer of InteRNA.
“Through the collaboration with InteRNA we gain access to a unique functional tool to identify microRNAs that are implicated in prostate carcinogenesis. Thus it is a truly symbiotic public-private partnership,” said Schalken.